The BTK inhibitors (ibrutinib, zanubrutinib, rilzabrutinib) have a potential therapeutic role in B-cell-mediated diseases other than anti-MAG antibody neuropathy, given their good profile (oral administration and favorable safety profile). The gene discussed is MAG; the disease is neuropathy.